Our group recently demonstrated that TP53-mutated MDS/AML and AML with erythroid features exhibit the highest levels of CCRL2 expression across the spectrum of MDS/AML subtypes(16). This evidence concerns the gene CCRL2 and acute myeloid leukemia.